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Background: Analytic morphometrics provides objective data that may better stratify risk. We investigated morphometrics and outcome among
colon cancer patients.
Methods: An IRB‐approved review identiﬁed 302 patients undergoing colectomy who had CT scans. These were processed to measure psoas area
(PA), density (PD), subcutaneous fat (SFD), visceral fat (VF), and total body fat (TBF). Correlation with complications, recurrence, and survival
were obtained by t‐tests and linear regression models after adjusting for age and Charlson index.
Results: The best predictor of surgical complications was PD. PMH, Charlson, BMI, and age were not signiﬁcant when PD was considered. SF area
was the single best predictor of a wound infection. While all measures of obesity correlated with outcome, TBF was most predictive. Final
multivariate Cox models for survival included age, Charlson score, nodal positivity, and TBF.
Conclusions: Analytic morphometric analysis provided objective data that stratiﬁed complications and outcome better than age, BMI, or
co‐morbidities.
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INTRODUCTION
Obesity, as measured by body mass index (BMI) has been associated
with both worse oncologic outcomes and increased morbidity of treatment
among patients with colorectal cancer, although the exact reasons are
unclear [1–4]. The impact of older age on colorectal cancer outcomes is also
a question, as older individuals are less represented in clinical trials andmay
be undertreated despite evidence of a survival beneﬁt with surgery and
adjuvant chemotherapy [5]. These clinical dilemmas are even more
concerning given that 40% of colorectal cancer patients in the U.S. are over
75 years of age, and obesity rates in the U.S. are rising dramatically [6,7].
However, chronologic age can be a poor measure of the relative frailty or
vitality of an individual, and BMI, while a useful clinical tool, is a relatively
non‐speciﬁc assessment of body composition that does not directlymeasure
adiposity. Use of these isolated values may not paint an accurate
physiologic portrait of the patient.
Analytic morphometric analysis, using morphometric measures
obtained from pre‐treatment imaging such as core muscle size, body
composition, bone mineral density, etc., provides objective data that
may better stratify risk. We have previously demonstrated that such
measures improve preoperative risk stratiﬁcation [8,9], predict for post‐
operative complications [10,11], and interestingly may also predict
oncologic outcome [10]. Given our previous observations, we therefore
sought to determine whether analytic morphometric analysis might not
only predict surgical complications among colorectal cancer patients,
but also long‐term outcome.
METHODS
Patients
An IRB‐approved retrospective review was performed of all patients
undergoing resection for colon cancer at the University of Michigan
between 2000 and 2010. Of the 515 patients whowere identiﬁed, 315 had
CT scans of the abdomen and pelvis performed at the University of
Michigan and therefore could be included in the study. Patients with
extra‐hepatic metastases undergoing palliative operationswere excluded.
The remaining 302 patients comprised the study group. Patient and tumor
characteristics including age, gender, height and weight, presentation,
and medical co‐morbidities, as well as treatment data including type of
surgery, complications, and adjuvant therapy were obtained for every
patient. Recurrence and survival information was obtained from
computerized medical records and from the Tumor Registry.
Analytic Morphomics
CT scans were processed using semi‐automated algorithms
programmed into MATLAB v13.0 as described in previous
work [8,11]. These algorithms use novel, high‐throughput techniques
to identify the linea alba and the anterior abdominal skin along the
midline at each vertebral level from T12 to L4. The average distance
between the linea alba and the anterior skin along T‐12 to L4was labeled
the subcutaneous fat distance (SFD), and the average distance between
the anterior aspect of the vertebra and the linea alba was labeled the
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visceral anterior‐to posterior (AP) distance (VF). The sum of the SFD
and visceral AP distance was labeled the total AP distance, or total body
fat (TBF).
Both psoas area (PA) and psoas density (PD) were determined in our
study population. Cross‐sectional areas of the left and right psoas
muscles at the level of the fourth lumber vertebra (L4) were measured.
The area of the resulting enclosed regions was then computed to generate
the cross‐sectional area of the psoas muscles. Fatty inﬁltration of the
psoas muscle was assessed by measuring the density, in Hounsﬁeld
Units (HU), within these regions, with lower HU reﬂecting more fat
inﬁltration [12]. This highly reproducible method correlates with muscle
triglyceride content on muscle biopsy [13–15].
In order to compare morphomic measurements to a more
standardized and validated morbidity index, we also calculated the
Charlson co‐morbidity Index for each patient [16]. The Charlson co‐
morbidity index is based on a weighted score assigned to each of 17
comorbidities, based on the relative risk of mortality, and has been
validated in various larger populations [17–19]. The Charlson score has
speciﬁcally been utilized and validated in studying the morbidity and
mortality among colorectal cancer patients, including complications of
colorectal cancer surgery, and is commonly used as a control in this
setting [20–24].
Statistical Analysis
Patients’ anthropomorphic measurements, disease characteristics,
and the occurrences of complications after surgery were compared to the
morphometrics using two‐sample t‐ tests or analysis of variance
techniques when the number of groups exceeded two. Linear regression
models were used to assess the association between continuous
covariates. For time‐to‐event endpoints disease‐free and overall
survival, time was calculated from the date of surgery until disease
recurrence or death, or death, respectively. Patients not experiencing the
endpoint of interest were censored on the date of their last known clinical
follow‐up. Cox proportional hazard regression models were used to
assess the association with morphomic measurements, both univariately
and multivariately after adjusting for signiﬁcant patient characteristics
such as age and co‐morbidity index. For all statistical tests,P‐values at or
below 0.05 were considered signiﬁcant.
RESULTS
The details of the patient population are summarized in Table I. There
was no difference in mean PD between genders (53.0 for males, 54.6 for
females, P¼ 0.14) while TPA was expectedly greater for males (956.2
vs. 828.7, P< 0.0001). Table II shows the relationship between the
morphometric measurements and age, BMI, and Charlson score. Not
surprisingly, BMI was signiﬁcantly associated with all of the
morphometric measurements. Age was signiﬁcantly correlated with
PD, PA, and VF. Table II also demonstrates the interactions between
individual morphometrics.
There was no signiﬁcant past medical history in 107 (37%) of the
patients. A cardiovascular history was present in 30.4% of patients
(excluding hypertension). A pulmonary history was present in 13.1%.
Fifteen percent of the patients had diabetes (18 Type 1, 40 Type 2) and
22% of patients had a prior cancer history. We speciﬁcally examined the
relationship between themorphometrics and both the Charlson score and
speciﬁc co‐morbidities. The median Charlson score was 5 (range 0–17),
and was signiﬁcantly associated with PD, VF, and TBD (Table II).
Table III highlights the relationships betweenmorphometrics and the co‐
morbidity categories. Not surprisingly, diabetes was associated with
decreased PD and all the obesity measurements. Cardiac disease was
also strongly associated with all the measurements except for SFD.
Pulmonary disease was associated with decreased PD and increased total
body area. Decreasing PD was also more common in patients who had a
prior non‐colorectal cancer.
TABLE I. Patient and Tumor Characteristics for Study Cohort (n¼ 302)
Gender
Male 157 (52%)
Female 145 (48%)
Age
Average 67.9 12.4
Range 26 to 94
BMI
Median 28.7 8.0
Range 19 to 92.6
Charlson co‐morbidity index
0–2 24 (8%)
3–4 80 (26%)
5–7 160 (53%)
8–10 34 (11%)
>10 4 (1%)
Presentation
Screening 73 (24%)
Bleeding 138 (46%)
Abdominal symptoms 69 (23%)
Other 22 (7%)
Urgency
Elective 259 (86%)
Urgent 34 (11%)
Emergent 9 (3%)
Operation
Left hemicolectomy 27 Open, 5 laparoscopic
Right hemicolectomy 127 Open, 24 laparoscopic
Sigmoid colectomy 54 Open, 4 Laparoscopic
Transverse colectomy 26 Open
LAR 17 Open, 3 laparoscopic
Total abdominal colectomy 8
Total proctocolectomy 4
Hartmann’s procedure 3
Histology
Ordinary 206 (68%)
Mucinous 30 (10%)
Features of MIS 20 (7%)
Dysplasia or well‐differentiated
CA in an adenoma
27 (9%)
Poorly differentiated 7 (2%)
Other (spindle cell, papillary,
anaplastic, small cell)
12 (4%)
T Stage
T1 43 (14%)
T2 47 (16%)
T3 177 (59%)
T4 28 (9%)
Benign 7 (2%)
N Stage
NX 1 (<1%)
N0 175 (58%)
N1 71 (24%)
N2 48 (16%)
n/a 7 (2%)
M Stage
M0 262 (87%)
M1 33 (11%)
n/a 7 (2%)
Overall Stage
I 73 (24%)
IIA 92 (30%)
IIB 8 (3%)
IIIA 14 (5%)
IIIB 52 (17%)
IIIC 23 (8%)
IV 33 (11%)
n/a 7 (2%)
Adjuvant chemotherapy
Yes 115 (38%)
None 169 (56%)
Unknown 18 (6%)
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Adjuvant chemotherapy was used in 113 patients (45.3%) and not in
158 patients (54.7%). For 18 patients, it was unclear whether they
received adjuvant chemotherapy. The use of adjuvant chemo was
signiﬁcantly higher among patients with higher PD (P¼ 0.003) but did
not correlate with any of the obesity measures, BMI or Charlson score.
Sarcopenia and Complications of Surgery
Overall 174 patients (58%) had some type of complication, which
were categorized as either infectious or non‐infectious. Infectious
complications occurred in 90 patients, and primarily consisted of wound
infections, which occurred in 44 patients (14.5%), but also included
intraabdominal abscess (12), urinary tract infections (24), septicemia (3),
pneumonia (10), and C. Diff colitis (8). Some patients hadmore than one
complication. Non‐infectious complications primarily consisted of
prolonged ileus requiring a longer hospital stay (26) and bleeding
complications (14), but also included DVT or PE (5), post‐operative
rhythm disturbances (4) and other complications. Twenty‐six patients
had both an infectious and non‐infectious complication.
The single best predictor of any complication versus none was PD
(OR 0.96 (0.94, 0.99), P¼ 0.004). When considering PD, Charlson
score, age or any speciﬁc co‐morbidity (cardiac disease, pulmonary
disease, or diabetes) were not statistically signiﬁcant. We further broke
down non‐infectious versus infectious complications. On univariate
analysis, the probability of developing an infectious complication was
signiﬁcantly associated with both decreasing PD (P¼ 0.03) and
increasing SFD (P¼ 0.003). Neither the Charlson Comorbidity Index,
age or BMI was signiﬁcantly associated with an infectious complication
(P¼ 0.10 and P¼ 0.63, respectively). There was also no signiﬁcant
association between infectious complications and cardiac disease
(P¼ 0.74), pulmonary disease (P¼ 0.10) and diabetes (P¼ 0.64). On
multivariate analysis, the strongest predictor of an infectious
complication was PD [OR 0.95 (0.93, 0.98) for every unit change,
P¼ 0.001].
When this was further broken down to look speciﬁcally at wound
infections, univariate analysis found that a wound infection was
signiﬁcantly more likely in patients with increased obesity, regardless of
how you measured it. There was no correlation between development of
a wound infection, age or speciﬁc co‐morbidities (cardiac disease,
pulmonary disease, diabetes or prior cancer). Using backwards
selection, the single best predictor of a wound infection following
colon cancer surgery was SFD (OR 1.05 (1.02, 1.08) for every unit
change of 10, P¼ 0.003).
Sarcopenia and Colon Cancer Outcomes
To study whether morphomics may be related to tumor biology in
colon cancer, we examined both stage at presentation and outcomes.
Patients who had colectomy for what turned out to be benign disease
were excluded. None of the measurements of sarcopenia (PD) or obesity
(VF, SFD, TBF, or BMI) correlated with histology, T‐stage or N‐stage.
Even comparing patients with liver metastases (M1) to those without
(M0), there was no signiﬁcant difference in any measure. The lack of
correlation between M stage and PD suggests that the presence of
sarcopenia in these patients does not appear to be related to tumor
burden. Overall American Joint Commission on Cancer (AJCC) Stage
also did not correlate with any of the morphometric measurements.
The median follow‐up for this patient population was 2.81 years
(mean of 3.23 years). At the time of the last follow‐up, 65% were alive
without disease and 12 patients (4%) were alive with disease. There were
92 patients who died, 48 (16%) having succumbed to metastatic
colorectal cancer while 44 (15%) died without evidence of disease.
Excluding the patients with M1 disease, or those patients undergoing
colectomy for what turned out to be benign disease, we examined the
impact of morphometrics on disease‐free and overall survival in the
context of Charlson score. On initial univariate analysis, PD, TBF, and
Charlson score were signiﬁcantly associated with both disease‐free and
overall survival, as shown in Table IV. Final multivariate models for
DFS and OS were controlled for both age and Charlson score. After
controlling for these, PD was no longer a signiﬁcant predictor of
outcome. However, TBFwas still signiﬁcantly associated with outcome.
Our ﬁnal multivariate Cox model for DFS included age, Charlson co‐
morbidity index, nodal positivity, and TBF (Table V).
DISCUSSION
Cancer of the colon and rectum is the 4th most common malignancy
in the United States, with an estimated incidence of 141,210 new cases in
2011 [25]. The majority of these patients are candidate for curative
resection, an operation that unfortunately carries a high risk of
complication, with morbidity ranging from 20% to 45% [26–29].
Numerous risk factors have been associated with the occurrence of
postoperative complications in colorectal surgery, including age, BMI,
the presence of excess SFD, presence of diabetes, and nutritional status
as reﬂected by serum albumin level. Operative process measures
associated with postoperative complications include duration of
operative procedure, the receipt of blood transfusion, glycemic control,
intraoperative hypothermia, and the timing and dosing of perioperative
antibiotics.
Patient frailty has been considered to be a risk factor for adverse
postoperative outcomes, but is poorly quantiﬁed. Frailty has been
deﬁned as a biologic syndrome of decreased reserve and resistance to
stressors, resulting from cumulative declines across multiple physiologic
systems and causing vulnerability to adverse outcomes [30]. However,
assessment of frailty is difﬁcult, typically depending on multiple
subjective evaluations. Muscle density (also known as muscle
attenuation or myosteatosis), may serve as one objective measure of
frailty, as it is not only related to age, but also inactivity, weight gain,
insulin resistance, and metabolic status [31,32]. It has been associated
with abnormalities in glucose metabolism, type 2 diabetes and levels of
several inﬂammatory mediators including leptin, C‐reactive protein
(CRP), IL‐6, and tumor necrosis factor‐alpha (TNF‐a) [33–39]. Trunk
muscle attenuation, as measured in this study, is strongly associated with
functional capacity, impaired physical function and increased risk of
disability and injury in older adults [40–42]. Muscle attenuation also
TABLE IV. Signiﬁcant Associations Between Morphomics and Outcome on
Univariate Analysis
Variable
Disease‐free survival Overall survival
HR (95% CI) P‐value HR (95% CI) P‐value
Total body fat
(change of 10)
1.01 (1.00, 1.03) 0.03 1.01 (1.00,1.03) 0.04
Average psoas
density (change of 1)
0.97 (0.95, 1.00) 0.03 0.97 (0.95, 1.00) 0.04
Charlson co‐morbidity
index (change of 1)
1.27 (1.10, 1.48) 0.002 1.43 (1.21, 1.68) <0.0001
TABLE V. Best Multivariate Cox Model for Disease‐Free Survival
Variable Comparison HR (95% CI) P‐value
Age þ1 year 1.03 (1.00, 1.06) 0.08
Charlson score þ1 point 1.11 (0.89, 1.39) 0.36
Lymph node positive Yes vs. no 1.75 (1.07, 2.87) 0.03
Total body fat þ10 1.01 (1.00, 1.02) 0.03
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occurs in themuscles of young individuals with limited physical activity,
weight gain and metabolic abnormalities [43], and as such may identify
high‐risk patients irrelevant of chronologic age.
Indeed, PD was the single best predictor of whether the patient had
any complication, including both non‐infectious and infectious
complications. When breaking down the infectious complications
even further, PD was highly predictive of non‐wound infections while
SFD was the best predictor of a wound infection, consistent with
previous observations [11]. Neither the Charlson Comorbidity Index,
age nor BMI were accurate predictors of these complications when
morphometrics were taken into account. It is telling that while decreased
PD was associated with multiple co‐morbid conditions, it was the
signiﬁcant predictor while the presence of these conditions was not. This
suggests that it is the impact of these conditions on the patient that
increases risk rather than the condition itself. Typically surgeons base
their estimate of risk on the past medical history, but more objective
measurements of the biologic impact of these co‐morbidities may be a
better method to identify patients whereby risk outweighs beneﬁt.
This information, readily available from the preoperative CT scan
may allow for preoperative intervention and a reduction in surgical
complications. Frail patients (of all ages) are less able to participate in
the standard post‐operative recovery program, including early
ambulation and incentive spirometry, which may lead to increased
surgical complications (venous thromboembolism, prolonged ileus,
pneumonia) [8,44–46].
Exercise training, in general, can rapidly and signiﬁcantly improve
both aerobic capacity and strength of individuals, especially de‐
conditioned older individuals [47–49]. Preoperative interventions in
frail patients with osteoarthritis and colon cancer have shown rapid
increases in patients’ strength and walking capacity, in less than 4 to 6
weeks [50,51]. Mayo et al. [50,52] showed that for patients undergoing
scheduled colorectal surgery, including cancer, a prehabilitation
program consisting of walking and breathing exercises, could
improve functional exercise capacity and this was associated with
improved postoperative recovery. Based on these ﬁndings, the
University of Michigan has developed a targeted exercise intervention
to increase the muscular strength of older surgery patients needing colon
surgery. This program involves pedometer based walking programs
which have demonstrated excellent compliance, improvements in
exercise outcomes, and improved patient satisfaction [53–56].
The speciﬁc impact of prehabilitation programs on muscle
attenuation is less clear. Several studies have shown that a directed
exercise program can improve muscle attenuation. Taaffe et al. [57]
demonstrated how resistance exercises can impact muscle attenuation,
with decreases in fatty inﬁltration with exercise and increases after
cessation. Coker et al. [58] showed that a 12‐week high intensity aerobic
exercise program signiﬁcantly improved muscle attenuation. Hutch-
inson et al [59] showed how a 12‐week treadmill‐based program could
improve muscle attenuation among women with polycystic ovary
syndrome, which is characterized by an insulin resistant state. However,
these studies focused on thigh muscle attenuation, not trunk muscles
such as the psoas. What type of exercises might be best to improve PD is
less clear. It also remains unknown whether exercise‐based improve-
ments in muscle density would be associated with concurrent
improvements in glucose metabolism, insulin resistance, levels of
pro‐inﬂammatory cytokines, and whether this might improve surgical
outcomes. Further research is warranted, and is on‐going at the
University of Michigan.
We have previously reported the impact of sarcopenia on long‐term
outcomes among patients with stage III melanoma and found that
decreased psoas muscle density on CT was a highly signiﬁcant predictor
of outcome, along with tumor factors such as Breslow thickness and
ulceration, suggesting the biology of the host may impact the natural
history of the disease [10]. These results are not completely surprising
given the long‐theorized relationship between melanoma and the
immune system. A similar relationship is less well‐developed for
colorectal cancer. In this study, fatty inﬁltration of the psoas muscle was
not associated with stage of disease. While it was associated with both
DFS and OS on univariate analysis, after controlling for both age and
Charlson score, this was no longer signiﬁcant. A more careful analysis
shows that PD was primarily predictive of non‐colorectal cancer deaths
among these patients, suggesting that frailty (and perhaps the metabolic
or immunologic correlates) play less of a role in the natural history of
colorectal cancer than melanoma. This data is in line with data recently
reported by Peng et al. [60], who found that sarcopenia was not
associated with long‐term outcome among patients with colorectal
cancer metastases to the liver undergoing hepatic resection.
Total body fat, however, was a signiﬁcant predictor of outcome, and
ﬁgured into our best‐ﬁt multivariate Cox model for DFS along with age,
the Charlson co‐morbidity index and nodal involvement. While the
relationship between obesity and colorectal outcomes has been well
described, in most cases obesity is deﬁned by BMI. However, there is
wide variation in how precisely BMI describes body composition [61–
63]. Our results are consistent with others that have demonstrated that
more direct measurements of adiposity may predict colorectal cancer
outcomes better than BMI [64,65]. The impact of obesity on colorectal
cancer biology may be connected to adiposity, with proposed
mechanisms including alterations of glucose‐insulin dynamics,
hyperinsulinemia and insulin‐like growth factors, or estrogen
production by adipose tissue [66–70]. As BMI can be impacted by
muscle mass, direct measures of adiposity, such as morphometric
measurements, may better elucidate risk.
In conclusion, analytic morphometric analysis provided objective
data that stratiﬁed both complications of treatment and outcome better
than commonly used variables (age, BMI, co‐morbidities) among
patients with colorectal cancer. Speciﬁcally, decreasing PD is a
signiﬁcant predictor of surgical complications, increasing SFD is a
signiﬁcant predictor of wound infection and TBF is a signiﬁcant
predictor of outcome. Morphometric analysis of patients being
considered for colectomy is readily available data that may help
identify patients at increased risk of surgical complication, and may help
with adjuvant therapy decisions. Further research into the impact that
pre‐surgical conditioning may have on reversing sarcopenia and
adiposity, and thus decreasing surgical complications and improving
outcomes, are on‐going.
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